Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive, long-term respiratory disorder characterized by persistent breathing difficulties and restricted airflow, which worsen over time.1 The primary cause of COPD is predominantly linked to cigarette smoking, making it a major public health concern. In 2010, COPD ranked as the fourth leading cause of death worldwide, and projections indicated it has become the third leading cause by 2020.2 These exacerbations are not only costly but are also linked to increased mortality, underscoring the need for effective management strategies. Chronic obstructive pulmonary disease affects approximately 350 million people globally, although prevalence estimates vary widely across different regions and countries.3

The disease manifests in various forms, primarily emphysema and chronic bronchitis, leading to symptoms such as chronic cough, excessive mucus production, and difficulty breathing.4 One of the most severe manifestations of this disease is an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), a temporary worsening of symptoms that can sometimes require hospitalization. These exacerbations are costly and linked to increased mortality, underscoring the need for effective management strategies.5

Existing treatments for COPD are largely aimed at managing symptoms, as well as preventing exacerbations. The core components of COPD therapy include combinations of bronchodilators, such as long-acting β2-agonists (LABA) and long-acting anti-muscarinic agonists (LAMA), alongside corticosteroids (inhaled or oral) antibiotics6 mucolytics, and macrolides for patients with frequent exacerbations.7 However, these treatments carry significant risks. Corticosteroid use, for instance, increases the likelihood of pneumonia and mycobacterial infections by approximately 2 to 4 times in COPD patients.8 Additionally, broad-spectrum antibiotics do not reduce hospitalization duration, 30- or 90-day readmission rates, time to the next exacerbation, or mortality in non-ICU COPD patients. Moreover, these antibiotics are associated with adverse effects, such as diarrhea, skin rashes, and the development of antibiotic resistance among respiratory pathogens.6,9

This demonstrates the complexity of COPD, highlighting that a uniform approach to treatment often results in diverse outcomes, such as treatment intolerance, non-response, and unequal access to therapies.10 Therefore, there is an urgent need for innovative therapeutic approaches that target the underlying mechanisms of COPD rather than solely addressing symptoms.

Recent developments have focused on alternative strategies less prone to fostering antimicrobial resistance. These approaches aim to inhibit disease progression by targeting mechanisms that pathogens find harder to adapt to.11 Novel therapies are emerging that disrupt crucial microbial processes, such as inhibiting attachment and invasion or enhancing pathogen clearance by the immune system, representing a significant shift from traditional treatments.12

In summary, given the heterogeneous nature of COPD, it is essential to move beyond conventional symptom-focused treatments. This review summarizes the risk factors associated with COPD, outlines therapeutic strategies for managing non-esinophilic COPD and AECOPD, and explores emerging approaches that focus on immunological mechanisms. These novel strategies include the inhibition of key receptors (PAFr, ICAM-1, SA, and TLR), the targeting of critical proteins and enzymes (PKC, PKI3, EGFR, ST6GAL1, and annexin-1), the modulation of immune cells (such as macrophages), and the control of other factors, including oxidative stress and iron levels. Through these advances, there is hope for more effective and individualized treatments for COPD in the future.

Etiologies of COPD

Smoking remains the primary cause of COPD, with its effects often manifesting later in life.13 In recent years, significant progress has been made in understanding the causes and risk factors associated with COPD, especially through epidemiological research. However, ongoing research is essential to further refine treatment and management strategies for both individuals and the broader population. The increasing prevalence of COPD places a substantial burden on healthcare resources and has significant economic implications worldwide. Multiple risk factors, including comorbidities and environmental exposures, contribute to the exacerbations of COPD. These exacerbations, along with conventional therapies for managing COPD and AECOPD, are outlined in Table 1 and Table 2, respectively.

Table 1 Risk Factors of COPD and AECOPD

Table 2 List of Conventional Therapies Used to Treat COPD and AECOPD

Immunological Targets Receptors Platelet-Activating Factor Receptor (PAFr)

Platelet-activating factor (PAF) is a phospholipid mediator critical in inflammatory processes, acting on various cells such as platelets, endothelial cells, lymphocytes, and macrophages.45,46 Elevated PAF receptor (PAFr) expression in COPD patients’ respiratory tracts facilitates bacterial adherence and proliferation, contributing to acute and chronic respiratory infections.47 Pathogens like Streptococcus pneumoniae and Haemophilus influenzae interact with PAFr,48 activating intracellular pathways (eg, Ras/Raf, PI3K, Rho/Rec1), leading to cytoskeletal remodeling, enhanced pathogen survival, and membrane ruffling (Figure 1).

Figure 1 Platelet activating factor receptor (PAFr) inhibition as therapeutic approach for COPD.

Abbreviations, ANTHi, nontypeable Haemophilus Influenza; ChoP, phosphorylcholine; Ras, rat sarcoma, Raf, rapidly accelerated fibrosarcoma; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PI3K, Phosphoinositide 3-kinases; PIP3, Phosphatidylinositol (3,4,5)-trisphosphate; Akt, protein kinase B; Rho, guanine nucleotide-binding proteins; Rec1, recombination protein 1; GEFs, guanine nucleotide exchange factors; WASP, Wiskott-Aldrich syndrome protein; cdc42, cell division cycle protein; WAVE, WASP-family verprolin-homologous protein.

Environmental factors, including cigarette smoke, air pollution, and e-cigarette vapor, significantly elevate PAFr expression.49,50 Laboratory studies suggest nicotine may play a role in PAFr upregulation observed in nasal epithelial cells exposed to e-cigarette vapor. Similarly, cigarette smoke extract (CSE) has been shown to enhance the adhesion of S. pneumoniae and H. influenzae to human bronchial epithelial cells via PAFr.51

Studies also indicate that PAFr expression may contribute to other respiratory conditions, such as idiopathic interstitial lung disease.52,53 Potential therapeutic strategies focus on inhibiting PAFr or disrupting bacteria-choline phosphoryl interactions. Reported PAFr inhibitors are summarized in Table 3, highlighting their potential in mitigating pathogen adhesion and progression of COPD.

Intracellular Adhesion Molecule-1 (ICAM-1)

The transmembrane glycoprotein ICAM-1, also referred to as CD54, plays a significant role in humans. ICAM-1 is continuously expressed across multiple cell types, including endothelial cells, respiratory epithelial cells, and leukocytes.54 From a physiological perspective, ICAM-1 is critical for maintaining cell-to-cell interactions and facilitates the movement of white blood cells from the bloodstream into inflamed tissues, potentially triggering targeted immune responses to antigens.55 ICAM-1 supports T-cell-mediated host defense by activating cytotoxic T cells in association with MHC class I, and on antigen-presenting cells, it activates MHC class II-restricted T cells through co-stimulatory molecules.56

Abnormal levels of ICAM-1 are associated with conditions such as AIDS, cancer, and allergic asthma.57 One mechanism by which human rhinovirus (HRV) attaches to airway/lung epithelial cells—accounting for over 60% of the primary HRV group—is through the upregulation and modification of surface ICAM-1. This upregulation can result from external factors, such as cigarette smoke, or from the virus itself.58 Paradoxically, increased ICAM-1 expression appears to elevate susceptibility to viral infections. However, several bacterial and parasitic pathogens, including Haemophilus influenzae (NTHi) and Plasmodium falciparum, also utilize ICAM-1 to attach to and invade host cells.59 For example, a controlled study showed that treating pulmonary epithelial cells with NTHi led to a fourfold increase in ICAM-1 expression60 and a TNF-dependent rise in HRV39 binding.61 This finding suggests a mechanism for the exacerbated effects of bacterial and viral co-infections, offering insight into why COPD patients are especially vulnerable to combined infections with NTHi and HRV.62

ICAM-1 is critical for the binding of NTHi and up to 90% of HRV serotypes to bronchial and alveolar epithelial cells.48 When HRV’s canyon protein binds to the ICAM-1 receptor, it triggers inflammatory mediators—TNF-α, IL-1β, and IFN-γ—resulting in cell inflammation (Figure 2). Further data is needed to determine the frequency of NTHi utilizing this adhesion mechanism. The example of ICAM-1 inhibitor is enlisted in Table 3.

Table 3 Non-Eosinophilic Immunological Targets for COPD and AECOPD

Figure 2 Intracellular adhesion molecule-1 (ICAM-1) inhibition as therapeutic approach for COPD.

Abbreviations, HRV, human rhinovirus; TNF-α, tumor necrosis factor-α; IL-1β, Interleukin 1β; IFN-γ, Interferon γ.

Sialic Acid (SA)

Sialic acids (SAs) are a group of nine-carbon monosaccharides prominently located on the outer surface of mammalian cells, particularly on glycoproteins within the cell membrane. These residues play a pivotal role in numerous biological processes, including the stabilization of glycoproteins and cellular membranes, as well as facilitating cell-cell recognition and interactions.93 Elevated levels of SA have been observed by Bel’skaya et al94 in both the blood and saliva of individuals with COPD, indicating a potential link to disease progression.

In terms of viral infection, influenza viruses primarily utilize sialic acid residues to enter bronchoepithelial cells (BECs). The viral hemagglutinin protein (HA-A) binds specifically to glycoproteins terminated with SA residues on host cells, particularly targeting SAα2,6Gal and SAα2,3Gal residues found on surface and inner respiratory epithelial cells. These residues serve as attachment points for human and avian influenza viruses.95 Following attachment, the virus is taken into the cell via endocytosis and encapsulated in an endosome. The acidic environment within the endosome induces a conformational change in the viral HA-A protein, facilitating fusion with the endosomal membrane and subsequent release of viral genes into the host cytoplasm.96 Upon contact with SA receptors, the influenza virus activates protein kinase C (PKC) and protein kinase R (PKR), which subsequently activate multiple inflammatory pathways. PKC activates the MEK/ERK and PI3K pathways, while PKR triggers the MAPK, IKK, and IPS-1 pathways, ultimately resulting in cell reorganization and inflammation through the activation of c-Jun, NF-kB, and IRF397 (Figure 3). Some reported SA inhibitors are enlisted in Table 3.

Figure 3 Sialic acid (SA) inhibition as therapeutic approach for COPD.

Abbreviations: HA, Heamagglutinin; PLC, phospholipase C; PKC, Protein kinase C; ERK, extracellular signal regulated kinase; PKR, Protein kinase R; PKR-P, Protein kinase R-phosphorylated; MAPK, Mitogen activated protein kinase; IKK, IκB kinase; IPS-1, Interferon-β Promoter Stimulator 1; c-Jun, A component of the activator protein 1; Nf-kB, Nuclear factor kappa B; IRF3, Interferon regulatory factor 3.

TLR-Mediated Response

The disruption of macrophage responses via Toll-like receptors (TLRs) plays a critical role in the development and progression of chronic obstructive pulmonary disease (COPD).98 Research suggests that chronic bacterial colonization or infection, combined with exposure to cigarette smoke, can overstimulate the immune system through TLRs, leading to inflammation and subsequent airway remodeling and lung tissue damage99 (Figure 4). In COPD patients, TLR activation, particularly through TLR3, TLR7, and TLR8 in response to viral triggers, has been associated with elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor (TNF) and CTLA-5.100 Additionally, TLR4 activation, followed by TLR2 activation in alveolar macrophages, contributes to increased cytokine production.98

Figure 4 TLR inhibition as therapeutic approach for COPD.

Abbreviations: NTHi, nontypeable Haemophilus Influenza; OMP P1, Outer membrane protein P1; UspA1, Ubiquitous surface protein A1; EGFR, Epidermal growth factor receptor; TLR, Toll-like receptor; IL-1β, Interleukin 1β; IFN-γ, Interferon γ; TNF, tumor necrosis factor; IL-12, Interleukin 12.

TLR2 and TLR4 are especially crucial for recognizing Gram-positive and Gram-negative bacteria’s pathogen-associated molecular patterns (PAMPs), respectively.101 Upon ligand binding, TLR2 and TLR4 initiate a MyD88-dependent signaling pathway that activates the mitogen-activated protein kinase (MAPK) cascade and nuclear factor-κB (NF-κB), leading to the release of pro-inflammatory mediators.102 This MyD88 pathway is central to TLR signal transduction.100 COPD patients frequently have bacterial colonization of the lower airways with pathogens such as Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis.103–105 Some reported TLR inhibitors are enlisted in Table 3.

Enzymes/Proteins Phosphodiesterase (PDE)3 and PDE4

Inhibitors of phosphodiesterase (PDE)3 and PDE4 play a crucial role in managing various respiratory functions.106 PDE3 is responsible for regulating the levels of cyclic AMP (cAMP) and cyclic GMP (cGMP) in airway smooth muscle, which directly influences bronchial tone.107 On the other hand, PDE4 primarily regulates cAMP and is involved in the activation and migration of inflammatory cells, as well as stimulating the cystic fibrosis transmembrane conductance regulator in bronchial epithelial cells.108

The dual inhibition of both PDE3 and PDE4 has demonstrated enhanced or synergistic effects compared to targeting either enzyme alone. This combined approach improves airway smooth muscle contraction and reduces inflammatory responses, making it a promising strategy for treating obstructive and inflammatory respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis, and asthma.109,110

Protein Kinase C (PKC)

The protein kinase C (PKC) superfamily plays a central role in numerous signaling pathways, influencing processes such as membrane dynamics, immune responses, gene expression, and cell growth.111 PKCs are particularly important in viral infections, as influenza viruses and their hemagglutinin (HA) proteins can rapidly activate PKC enzymes upon binding to host cell receptors.112 Experimental studies have shown that inhibiting PKCs can impair viral entry and infectivity in enveloped viruses, including influenza A and B, underscoring the role of PKC in viral cell entry.113 Specifically, PKC activation leads to the stimulation of the MEK/ERK and PI3K pathways, promoting cytoskeletal reorganization and inflammation, which support viral entry (Figure 5).

Figure 5 Protein kinase C Inhibition as therapeutic approach for COPD.

Although the precise mechanisms by which PKCs facilitate viral entry are not fully understood, PKCbII isoform appears to be critical for the late endosomal sorting required for influenza virus entry.114 PKC activation by respiratory syncytial virus (RSV) in A549 lung epithelial cells has also been shown to increase expression of several PKC isoforms, activating extracellular signal-regulated kinases essential for cell fusion and infection.115 Inhibitory drugs administered early in infection significantly blocked RSV infection in NHBE cells by targeting PKC, suggesting that pharmacological PKC inhibition may be a viable strategy for controlling influenza and RSV by preventing virions from entering host cells116 (Table 3).

Phosphoinositide 3-Kinase (PI3K)

The influenza virus’s non-structural protein 1 (NS1) directly interacts with the p85 subunit of phosphoinositide 3-kinase (PI3K), leading to the activation of PI3K and downstream Akt signaling.117,118 PI3K plays a vital role in cellular processes like inhibiting apoptosis, promoting cell growth, regulating metabolism, and initiating cytokine production (Figure 6).119 Several investigations have linked PI3K in facilitating effective viral proliferation.120 PI3K’s activation has been linked to enhanced viral proliferation, as it facilitates virus entry, viral RNA synthesis, protein production, and the prevention of premature cell death, all of which are critical for effective viral replication.121

Figure 6 Phosphoinositide 3-kinase inhibition as therapeutic approach for COPD.

Individuals with COPD exhibit hyper-expression of PI3K in lung tissues, a factor that increases their vulnerability to viral infections and may contribute to the disease’s progression.85,122 The severity of airflow obstruction in COPD patients has been correlated with elevated PI3K levels and decreased levels of PTEN, a negative regulator of the PI3K pathway.123 Cigarette smoke extract (CSE) further exacerbates this effect by reducing PTEN expression in bronchial epithelial cells, leading to increased Akt phosphorylation and the release of proinflammatory cytokines.124,125

Studies have identified PI3K isoforms that are particularly implicated in COPD pathology. The PI3K-p110α isoform is notably overexpressed in primary bronchial epithelial cells (pBECs) from COPD patients. Reducing p110α expression prior to infection has been shown to decrease viral effects and enhance the antiviral response mediated by IFN-β, particularly in healthy and COPD-affected primary bronchial cells.126 This isoform-specific targeting could enable the development of selective inhibitors that minimize unintended effects. Another PI3K isoform, PI3Ky, which is primarily expressed in hematopoietic cells, plays a role in immune responses to viral infections, although its involvement in COPD remains unexplored.127 Example is enlisted in Table 3.

Epidermal Growth Factor Receptor (EGFR)

The epidermal growth factor receptor (EGFR), a receptor kinase, plays a key role in tissue repair, mucin synthesis, and IL-8 production in lung epithelial cells, particularly in response to elastase.128 Viral infections, including those caused by influenza and human rhinovirus (HRV), have been shown to enhance EGFR activation and IL-8 production in bronchial epithelial cells, contributing to increased viral adherence to airway tissues.129 Research suggests that EGFR facilitates influenza A virus infection via the PI3K/Akt signaling pathway, indirectly promoting viral proliferation.130

Chronic EGFR activation, whether due to viral infections or impaired antioxidant defense in COPD, can lead to airway remodeling and subsequent airway narrowing—a key pathological feature of COPD.131 EGFR also supports the antiviral response mediated by interferon (IFN), although viral infections like influenza A and HRV can suppress IFN-γ production, increasing viral replication in bronchial cells.58,132 Blocking EGFR has been shown to enhance IFN-γ levels and reduce viral load in both in vitro and in vivo studies, highlighting EGFR inhibition as a promising antiviral strategy.

In addition to its role in viral infections, EGFR activation is also stimulated by bacteria like Moraxella catarrhalis, which commonly exacerbates COPD symptoms.133,134 EGFR inhibition may therefore offer a dual benefit, reducing COPD exacerbations from bacterial and viral sources while addressing the underlying disease mechanisms (Table 3).

ST β-Galactoside Alpha-2,6-Sialyltransferase 1 (ST6GAL1)

Glycosylation, the attachment of sugar molecules to proteins and lipids, plays an essential role in regulating various cellular processes in eukaryotic cells, affecting both physiological and pathological states.135 One key glycosylation enzyme, ST6GAL1, is a type II membrane protein localized mainly in the Golgi apparatus and is responsible for transferring sialic acid from CMP-sialic acid to galactose-containing glycans.136,137 Through this sialylation, ST6GAL1 influences critical molecular pathways, including Notch1, Hes1, MMPs, and VEGF, which are known to play a role in lung cancer progression. Alterations in α2-6 sialylation have been specifically implicated in promoting lung cancer, highlighting ST6GAL1’s importance in cancer-related pathways.138

In the context of respiratory diseases, ST6GAL1 has been associated with airway mucin regulation and changes in sialylation levels in asthma, contributing to altered cell proliferation and inflammation.139 However, studies on ST6GAL1’s role in other chronic lung disorders remain limited, and its exact functions within these conditions are not yet fully understood.

Krick et al140 explored ST6GAL1’s role in inflammation by examining its effects on IL-6 production in human bronchial epithelial cells (HBECs). They found that ST6GAL1 deficiency led to elevated IL-6 production and release. Exposure to cigarette smoke medium or extract (CSE), as well as inhibition of BACE1, further suppressed ST6GAL1 secretion, reduced α2-6 sialylation, and increased IL-6 levels in HBECs. This relationship between ST6GAL1 and IL-6 suggests that decreased ST6GAL1 levels, with subsequent α2-6 sialylation reduction, might exacerbate inflammation in the lungs.

Additionally, a study on a small group of COPD patients revealed that lower plasma ST6GAL1 levels were correlated with a higher risk of future acute exacerbations of COPD (AECOPD), whereas IL-6 levels showed a positive correlation with exacerbation risk. These findings suggest that reduced ST6GAL1 and α2-6 sialylation levels may contribute to worse clinical outcomes in COPD through heightened inflammation, specifically by increasing IL-6 levels. This insight points to ST6GAL1 and α2-6 sialylation as potential biomarkers and therapeutic targets for managing inflammation in COPD and possibly other chronic lung diseases.

Annexin-1

Annexin A1, a polyunsaturated fatty acid-containing molecule, plays a crucial role in resolving neutrophilic inflammation by enhancing efferocytosis, the process through which dying neutrophils are cleared, and by inhibiting further recruitment of neutrophils.141 As a pro-resolving molecule, annexin A1 is increasingly viewed as a therapeutic target, particularly due to its roles in inflammation and in infections, such as those caused by nontypeable Haemophilus influenzae (NTHi).142 Interestingly, while increased levels of annexin A1 facilitate influenza virus binding, replication, and nuclear translocation from endosomes, mice lacking annexin A1 have demonstrated increased survival rates and reduced viral loads during influenza A infections, alongside a rise in inflammatory cell infiltration.143

In the context of COPD, annexin A1 has shown variable associations with disease severity. Higher serum levels of annexin A1 have been linked to more severe cases of COPD, suggesting an impaired inflammation-resolving capacity within the chronic inflammatory environment typical of the disease. Similarly, increased or dysfunctional pro-resolving mediator levels have also been noted in conditions like inflammatory bowel syndrome, preeclampsia, and Alzheimer’s disease, suggesting that a common pathway involving dysfunctional inflammation resolution may be at play across these chronic conditions.144

However, another study involving a larger participant pool found that serum annexin A1 levels were lower in COPD patients compared to healthy non-smokers. Both studies agree, though, that annexin A1 expression in human bronchial epithelial (HBE) cells increases in response to cigarette smoke extract (CSE), and this expression correlates with COPD severity.145 The discrepancy between these studies remains unexplained but could relate to sample variation, underscoring the need for further research to clarify annexin A1’s role in COPD.

Modulating pro-resolution molecules like annexin A1 offers potential therapeutic benefits, including slowing COPD progression, reducing airway wall thickness, and preventing virus-induced exacerbations.146 Such interventions might also prove beneficial for other lung conditions marked by reduced macrophage-mediated efferocytosis, such as cystic fibrosis (CF) and interstitial pulmonary fibrosis (IPF).147 This potential highlight the need to investigate annexin A1 and similar molecules as part of targeted therapies for inflammatory lung diseases.

Immune Cells Macrophages

Macrophages are essential for lung defense against pathogens, utilizing Toll-like receptors (TLRs) to recognize pathogen-associated molecular patterns (PAMPs).148 Lung macrophages adapt by modulating their functions and phenotypes in response to diverse stimuli,149 with two main types involved, classically activated M1 and alternatively activated M2 macrophages.150 M1 macrophages respond to bacterial antigens and IFN-γ by enhancing Th1 immunity and releasing pro-inflammatory cytokines, including IL-1β, TNF, and IL-12, to eliminate pathogens.151

M1 macrophages also produce reactive nitrogen and oxygen species, which have bactericidal effects but can be toxic to host tissues.152 M2 macrophages counterbalance these effects, promoting tissue repair, fibrosis, and efferocytosis by releasing regulatory cytokines like IL-10 and TGF-β, often in response to stimuli like IL-4, IL-13, and apoptotic cells (Figure 7).153 This duality is essential for balanced immune responses but becomes dysregulated in chronic lung diseases like COPD.

Figure 7 Macrophage Inhibition as therapeutic approach for COPD.

In COPD, macrophage numbers increase, but their ability to clear pathogens and dead cells decreases, indicating a functional deficit.154,155 COPD-related airway macrophages shift towards an M1-dominated airway wall and an M2-polarized airway lumen, contributing to the chronic inflammatory environment typical of the disease.156 This shift may be an adaptive response to continuous insult from cigarette smoke and microbial colonization.157

One mechanism involved in this macrophage imbalance is the competition between iNOS (M1 marker) and arginase-1 (M2 marker), both of which utilize arginine. Elevated arginase-1 in COPD macrophages inhibits iNOS, compromising antimicrobial activity and encouraging collagen deposition, thereby promoting airway remodeling and infection susceptibility.158 Additionally, the phagocytic and efferocytic functions of macrophages are impaired in COPD, exacerbated by smoking, which reduces these functions even in healthy smokers.159,160 Some reported macrophages inhibitors are enlisted in Table 3.

Others Oxidative Stress

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) play essential roles in the immune response against pathogens. While they exhibit antimicrobial activity, their excessive accumulation or inadequate removal—due to impaired antioxidant defenses—leads to oxidative damage, impacting DNA, lipids, and proteins.161 Chronic oxidative stress, a hallmark of COPD, contributes significantly to airway damage, with ROS production sustained even after smoking cessation, suggesting additional endogenous factors like persistent infection or pathogens in ROS accumulation.162,163

In COPD models, ROS generation intensifies in response to bacterial and viral attacks.164 Although ROS has a protective role, excessive levels compromise phagocytosis and efferocytosis, reducing pathogen clearance and perpetuating an overactive ROS response.165 Targeting this oxidative load in COPD could involve enhancing antioxidant enzyme activity or inhibiting ROS-producing enzymes like NADPH oxidases (NOX).166

The NOX2 isoform, primarily responsible for ROS production in inflammatory cells, is pivotal for ROS generation directed against bacterial and fungal invaders.167 Yet, studies suggest NOX2 activation might exacerbate viral infections, as seen with influenza A virus, where NOX2 absence led to reduced lung inflammation and viral load in mice.168 These findings underscore NOX2’s role in COPD, where its increased gene expression correlates with airway inflammation.169 Inhibiting NOX2 with compounds like apocynin has shown efficacy in lowering airway inflammation, viral titers, and ROS levels in COPD mouse models,170,171 although immunosuppressive risks remain a concern.172

Other NOX isoforms may also influence COPD progression. For example, NOX4, activated by cigarette smoke, may contribute to airway remodeling in small airways.153,173 Consequently, selective targeting of NOX isoforms could optimize therapeutic efficacy and reduce ROS production in COPD patients.

Enhancing antioxidant enzyme activity, particularly through glutathione peroxidase (Gpx) and superoxide dismutase (SOD) modifications, represents another approach to reduce oxidative stress in COPD. These enzymes neutralize superoxide radicals, primarily generated during cellular respiration.174 Gpx1, found extensively in lung tissues, and extracellular SOD (SOD3) have demonstrated protective effects in animal COPD models. Gpx and SOD mimetics, including ebselen, have shown promising effects in reducing inflammation and protecting lung tissue during viral infections like influenza.175 Interestingly, genetic variations in SOD3 have been linked to COPD susceptibility, with certain SOD3 mutations providing protective effects, particularly in smokers.164,166,176 While reducing ROS production or boosting antioxidant capacity could theoretically alleviate COPD exacerbations and progression, research on these interventions’ efficacy and safety in humans remains limited. By clarifying ROS’s role in viral pathogenicity and COPD development, we can potentially devise effective, comprehensive treatments for COPD management.

Iron

Recent research has revealed a concerning link between iron accumulation in the lungs and the progression of pulmonary disorders, particularly pulmonary fibrosis, asthma, and COPD. Studies have found a correlation between elevated iron levels in the lungs and increased airflow obstruction and emphysema severity, suggesting that iron is a key factor in COPD pathology. Proteomic and genome-wide association studies (GWAS) also support the involvement of iron-related genes in worsening airway symptoms, further establishing this association.177,178

Experiments using animal models have shown that chelation therapy, which removes free iron, can alleviate cigarette smoke-induced emphysema. This finding suggests that iron contributes to COPD susceptibility, potentially by fostering bacterial colonization and infection in the airways. Supporting this, cell-line studies indicate that iron overload can lead to lysosomal dysfunction and reduced bacterial killing capability. In experimental settings, the bactericidal function of murine alveolar macrophages was enhanced when iron was chelated, pointing to a direct influence of iron on immune cell function.179,180

Specifically, Ho et al179 explored whether elevated iron in sputum macrophages could increase the risk of infective acute exacerbations in COPD (AECOPD). Both interleukin-6 (IL-6) and hepcidin are known to play roles in iron sequestration within the lungs. Their study provided in vitro and population-based evidence suggesting that excess iron in pulmonary macrophages might lead to recurrent infections in COPD patients. They hypothesize that IL-6-mediated iron sequestration within sputum macrophages could impair immune cell function, resulting in higher infection rates and worsening COPD symptoms. Overall, these findings underscore the importance of understanding iron metabolism in COPD and exploring therapeutic strategies like iron chelation to limit iron’s adverse effects on airway health.

Conclusion

The optimal treatment of COPD continues to evolve, with a growing focus on therapies targeting specific molecular pathways involved in disease progression. While many biologics have been investigated, significant progress is still required to identify those that can effectively modify the disease and improve long-term outcomes. Current research highlights the importance of targeting specific immune responses to enhance the efficacy of treatments while minimizing the side effects seen with traditional therapies.

In terms of clinical trials, the outcomes for assessing efficacy are well-established at various stages of development. Phase 3 trials use a clear set of accepted outcome measures that are recognized by regulatory bodies, including lung function, exacerbation rates, and quality of life assessments. In Phase 2 trials, carefully selected biomarkers and surrogate endpoints are frequently explored to gauge early efficacy. The inclusion criteria for clinical trials vary depending on the mechanism of action of the therapy under investigation, and these criteria should be tailored to specific patient populations to ensure the trials’ relevance and validity.

Understanding the role of molecular and immunological targets in COPD pathology, as well as their influence on clinical outcomes, will guide the development of more effective and personalized treatments. Further research into biomarkers, the role of iron metabolism, and oxidative stress mechanisms will be key to refining treatment strategies and improving patient outcomes in COPD management.

Funding

This research was funded by the Science and Technology Development Plan Project of Jilin Province-Technology Innovation Guidance (Grant No. 20220401061YY), the Science and Technology Development Plan Project of Jilin Province-Key Research and Development (Grant No. 20230204055YY) and Norman Bethune Program of Jilin University (Grant No. 2023B34).

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan IJTLRM. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019, a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458. doi:10.1016/S2213-2600(21)00511-7

2. Halpin DRM. Mortality of patients with COPD. Exp Rev Respir Med. 2024;18(6):381–395. doi:10.1080/17476348.2024.2375416

3. Al Wachami N, Guennouni M, Iderdar Y, et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD), a systematic review and meta-analysis. BMC Public Health. 2024;24(1):297. doi:10.1186/s12889-024-17686-9

4. Vogelmeier CF, Roman-Rodriguez M, Singh D, Han MK, Rodriguez-Roisin R, Ferguson G. Goals of COPD treatment, focus on symptoms and exacerbations. Respiratory Medicine. 2020;166:105938. doi:10.1016/j.rmed.2020.105938

5. Prediletto I, Giancotti G, Nava CM. COPD Exacerbation, why it is important to avoid ICU admission. J Clin Med. 2023;12(10):3369. doi:10.3390/jcm12103369

6. Schellack N, Truter A, Ntuli P, Mokwele N, Mogale K, Esterhuizen AJSPJ. A 2021 update, approach to asthma management in adults. SA Pharm J 2021;88(4):17–24.

7. Rosenwasser Y, Berger I, Loewy ZGJP. Therapeutic approaches for chronic obstructive pulmonary disease (COPD) exacerbations. Pathogens. 2022;11(12):1513. doi:10.3390/pathogens11121513

8. Lineros R, Fernández-Delgado L, Vega-Rioja A, et al. Associated factors of pneumonia in individuals with chronic obstructive pulmonary disease (COPD) apart from the use of inhaled corticosteroids. Biomedicines. 2023;11(5):1243. doi:10.3390/biomedicines11051243

9. Muteeb G, Rehman MT, Shahwan M, Aatif MJP. Origin of antibiotics and antibiotic resistance, and their impacts on drug development, a narrative review. Pharmaceuticals. 2023;16(11):1615. doi:10.3390/ph16111615

10. Chellappan DK, Prasher P, Shukla SD, et al. Exploring the role of antibiotics and steroids in managing respiratory diseases. J Biochem Mol Toxicol. 2022;36(10):e23174. doi:10.1002/jbt.23174

11. Matera MG, Cazzola M, Page CJCOi P. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84. doi:10.1016/j.coph.2020.11.003

12. Buhr RG, Jackson NJ, Dubinett SM, Kominski GF, Mangione CM, Ong M. Factors associated with differential readmission diagnoses following acute exacerbations of chronic obstructive pulmonary disease. J Hosp Med. 2020;15(4):219–227. doi:10.12788/jhm.3367

13. Buttery SC, Zysman M, Vikjord SA, Hopkinson NS, Jenkins C, Vanfleteren LEJR. Contemporary perspectives in COPD, patient burden, the role of gender and trajectories of multimorbidity. Respirology (Carlton, Vic.). 2021;26(5):419–441. doi:10.1111/resp.14032

14. Bénézit F, Loubet P, Galtier F, et al. Non-influenza respiratory viruses in adult patients admitted with influenza-like illness, a 3-year prospective multicenter study. Infection. 2020;48(4):489–495. doi:10.1007/s15010-019-01388-1

15. D’Anna SE, Maniscalco M, Cappello F, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Annals of Medicine. 2021;53(1):135–150. doi:10.1080/07853890.2020.1831050

16. Liao K-M, Chen Y-J, Shen C-W, Ou S-K, Chen C-YCOPD. The influence of influenza virus infections in patients with chronic obstructive pulmonary disease. Int J Chronic Obst Pulm Dis. 2022;17:2253–2261. doi:10.2147/COPD.S378034

17. Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus–associated hospitalizations among adults with chronic medical conditions. Clinical Infectious Diseases, an Official Publication of the Infectious Diseases Society of America. 2021;73(1):e158–e163. doi:10.1093/cid/ciaa730

18. Satia I, Cusack R, Greene JM, O’Byrne PM, Killian KJ, Johnston N. Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma. PLoS One. 2020;15(2):e0228544. doi:10.1371/journal.pone.0228544

19. Walter JM. Other Respiratory Viruses as a Cause of Community-Acquired Pneumonia. Thieme Medical Publishers; 2020:579–591.

20. Nagabhushan B. A Prospective Study on Community Acquired Pneumonia With Special Reference to Its Etiology, Clinical Profile, Risk Factors, Complications, and Radiographic Features in Elder Age Group in a Tertiary Care Hospital. Rajiv Gandhi University of Health Sciences (India); 2020.

21. Nguyen-Van T, Pham-Hung V, Tran-Van N, et al. Microbial characteristics of lower respiratory tract infections in patients referred from primary care hospitals. J Health Sci Med Res 2024;42(3):20231004.

22. Zhuo X, Zhao J, Wang L, et al. Development and evaluation of a multiplex quantitative polymerase chain reaction assay for detecting bacteria associated with lower respiratory tract infection. Int J Infect Dis. 2022;122:202–211. doi:10.1016/j.ijid.2022.05.052

23. Song J, Qiu W, Huang X, et al. Association of ambient carbon monoxide exposure with hospitalization risk for respiratory diseases, a time series study in Ganzhou, China. Front Public Health. 2023;11:1106336.

24. Orellano P, Reynoso J, Quaranta N. Short-term exposure to sulphur dioxide (SO2) and all-cause and respiratory mortality, a systematic review and meta-analysis. Environ Int. 2021;150:106434.

25. Sharma R, Kurmi O, Hariprasad P, Tyagi SJIJo AE. Health implications due to exposure to fine and ultra-fine particulate matters, a short review. Int J Ambient Energy. 2024;45(1):2314256.

26. Pawankar R, Wang J-Y, Wang I-J, et al. Asia Pacific Association of allergy asthma and clinical immunology white paper 2020 on climate change, air pollution, and biodiversity in Asia-Pacific and impact on allergic diseases. Asia Pacific Allergy. 2020;10(1):e11. doi:10.5415/apallergy.2020.10.e11

27. Baniasad M, Mofrad MG, Bahmanabadi B, Jamshidi S. COVID-19 in Asia, transmission factors, re-opening policies, and vaccination simulation. Environ Res. 2021;202:111657. doi:10.1016/j.envres.2021.111657

28. Whittaker Brown S-A, Braman SS. Pulmonary Disease. Geriatric Medicine, A Person Centered Evidence Based Approach. Springer; 2023:1–26.

29. India LJLI. Lung India; 2013.

30. Al-Moamary MS, Alhaider SA, Alangari AA, et al. The Saudi initiative for asthma-2019 update, guidelines for the diagnosis and management of asthma in adults and children. Ann ThoracMed. 2019;14(1):3–48. doi:10.4103/atm.ATM_327_18

31. Sherry HY, Drucker AM, Lebwohl M, Silverberg JA. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733–740.e11. doi:10.1016/j.jaad.2017.09.074

32. Williams D. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655–670.

33. Gupta N, Haley R, Gupta A, Sethi S. Chronic Obstructive Pulmonary Disease in the Intensive Care Unit, Antibiotic Treatment of Severe Chronic Obstructive Pulmonary Disease Exacerbations. Thieme Medical Publishers; 2020:830–841.

34. Pratt AJ, Purssell A, Zhang T, et al. Complexity in clinical diagnoses of acute exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary Medicine. 2023;23(1):298. doi:10.1186/s12890-023-02587-1

35. Ammous O, Feki W, Lotfi T, et al. Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2023;1:1.

36. Cousins JL. Prescription of Acute Oxygen Therapy in Patients at Risk of Type Ii Respiratory Failure. The University of Newcastle; 2023.

37. Pagliaro R, Aronne L, Fomez R, et al. High-flow nasal cannula system in respiratory failure associated with interstitial lung diseases, a systematic review and narrative synthesis. J Clin Med. 2024;13(10):2956. doi:10.3390/jcm13102956

38. Ferrer M, De Pascale G, Tanzarella ES, Antonelli M. Severe Community-Acquired Pneumonia, Noninvasive Mechanical Ventilation, Intubation, and HFNT. Thieme Medical Publishers, Inc.; 2024:169–186.

39. Carrillo-Aleman L, Agamez-Luengas AA, Guia M, et al. Effectiveness and safety of non-invasive ventilation in the management of cardiogenic shock. Rev Portug Cardiol. 2024;43(5):259–273. doi:10.1016/j.repc.2023.08.006

40. Baraldi F, Barrecheguren M, Papi A, Miravitlles M. Managing exacerbations of COPD, how much progress have we made? Eur Respir Soc. 2024; 2024:283–296.

41. Longhini F, Vaschetto R, Navalesi P. Key messages. 2024:75.

42. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024;390(24):2274–2283. doi:10.1056/NEJMoa2401304

43. Sun C-Y, Tesfaigzi Y, Lee G-Y, Chen Y-H, Weiss ST, KS-K M. Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease, a 7-year population-based cohort study. J Allergy Clin Immunol. 2025;155(1):219–222.e1. doi:10.1016/j.jaci.2024.09.019

44. Yappalparvi A, Balaraman AK, Padmapriya G, et al. Safety and efficacy of ensifentrine in COPD, a systemic review and meta-analysis. Respir Med. 2025;236:107863. doi:10.1016/j.rmed.2024.107863

45. Nisa A, Kipper FC, Panigrahy D, Tiwari S, Kupz A, Subbian SJAJo P-CP. Different modalities of host cell death and their impact on Mycobacterium tuberculosis infection. Am J Physiol Cell Physiol. 2022;323(5):C1444–C1474.

46. Upton JE, Grunebaum E, Sussman G, Vadas PJB. Platelet activating factor (PAF), a mediator of inflammation. BioFactors (Oxford, England). 2022;48(6):1189–1202. doi:10.1002/biof.1883

47. Shukla SD, Walters EH, Simpson JL, et al. Hypoxia‐inducible factor and bacterial infections in chronic obstructive pulmonary disease. Respirology (Carlton, Vic.). 2020;25(1):53–63. doi:10.1111/resp.13722

48. Brown MA. The Epithelial Cell in Host-Pathogen Interactions in Airways Disease. University of Oxford; 2022.

49. Beentjes D, Shears RK, French N, Neill DR, Kadioglu A, Medicine CC. Mechanistic insights into the impact of air pollution on pneumococcal pathogenesis and transmission. Am J Respir Crit Care Med. 2022;206(9):1070–1080. doi:10.1164/rccm.202112-2668TR

50. Rajendra KC. Exploring Molecular Mechanisms Underlying the Role of Non-Typeable Haemophilus Influenzae in COPD. University of Tasmania; 2020.

51. Kalininskiy A, Kittel J, Nacca NE, Misra RS, Croft DP, McGraw M. E-cigarette exposures, respiratory tract infections, and impaired innate immunity, a narrative review. Pediat Med. 2021;4. doi:10.21037/pm-20-97

52. Bagam P. Role and Regulation of Autophagy Mechanism During Cigarette Smoke Exposure. Southern University and Agricultural and Mechanical College; 2020.

53. Ferraro M, Di Vincenzo S, Lazzara V, et al. Formoterol exerts anti-cancer effects modulating oxidative stress and epithelial-mesenchymal transition processes in cigarette smoke extract exposed lung adenocarcinoma cells. Int J Mol Sci. 2023;24(22):16088. doi:10.3390/ijms242216088

54. Gusev SJJCIM. Analysis of the level of IgG to SARS-CoV-2 virus and molecular markers of activation of CD25, CD54 (ICAM-1) and CD95 lymphocytes in the patients who were not ill with COVID-19, recovered from COVID-19 and who had acute respiratory infections. The results of the correction of impaired immune homeostasis using the multitarget immunotherapy drug mercureid. J Clin Immunol Microbiol. 2022;3(3):1–17.

55. BJIjoms C. Secretome and tunneling nanotubes, a multilevel network for long range intercellular communication between endothelial cells and distant cells. Int J Mol Sci. 2021;22(15):7971. doi:10.3390/ijms22157971

56. Uhl LF, Gérard AJIJo MS. Modes of communication between T cells and relevance for immune responses. Int J Mol Sci. 2020;21(8):2674. doi:10.3390/ijms21082674

57. Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-related lung disease, immunity, infection, and inflammation. Physiol Rev. 2020;100(2):603–632. doi:10.1152/physrev.00039.2018

58. Shukla SD, Shastri MD, Vanka SK, et al. Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases. Inflammopharmacology. 2022;30(3):725–735. doi:10.1007/s10787-022-00968-2

59. Osii RS, Otto TD, Garside P, Ndungu FM, Brewer JMJFi I. The impact of malaria parasites on dendritic cell–T cell interaction. Front Immunol. 2020;11:1597. doi:10.3389/fimmu.2020.01597

60. Avadhanula V, Rodriguez CA, Ulett GC, Bakaletz LO, Adderson EEJI. immunity. Nontypeable Haemophilus influenzae adheres to intercellular adhesion molecule 1 (ICAM-1) on respiratory epithelial cells and upregulates ICAM-1 expression. Infect Immun. 2006;74(2):830–838. doi:10.1128/IAI.74.2.830-838.2006

61. Michi AN, Yipp BG, Dufour A, Lopes F, Proud DJNC. PGC-1α mediates a metabolic host defense response in human airway epithelium during rhinovirus infections. Nature Commun. 2021;12(1):3669. doi:10.1038/s41467-021-23925-z

62. Nesbitt H, Burke C, Haghi M. Manipulation of the upper respiratory microbiota to reduce incidence and severity of upper respiratory viral infections, a literature review. Front Microbiol. 2021;12:713703. doi:10.3389/fmicb.2021.713703

63. Hyland I. Synthesis and Functionalisation of Heterocyclic Molecules With Bioactive Properties. University Of Tasmania; 2020.

64. Sharif NAJB. PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists, cell and nuclear effects. Biofactors. 2022;48(6):1226–1249.

65. Cima Cabal MD, Molina F, López-Sánchez JI, Pérez-Santín E, Del Mar García-Suárez M. Pneumolysin as